1. Home
  2. ACAD vs KBH Comparison

ACAD vs KBH Comparison

Compare ACAD & KBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.18

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo KB Home

KBH

KB Home

HOLD

Current Price

$52.48

Market Cap

3.8B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACAD
KBH
Founded
1993
1957
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.8B
IPO Year
2000
1994

Fundamental Metrics

Financial Performance
Metric
ACAD
KBH
Price
$22.18
$52.48
Analyst Decision
Buy
Hold
Analyst Count
22
14
Target Price
$30.55
$56.17
AVG Volume (30 Days)
1.4M
1.0M
Earning Date
05-06-2026
03-24-2026
Dividend Yield
N/A
1.84%
EPS Growth
69.12
N/A
EPS
2.30
0.52
Revenue
$726,437,000.00
$4,547,002,000.00
Revenue This Year
$18.80
N/A
Revenue Next Year
$11.70
$9.23
P/E Ratio
$9.87
$104.74
Revenue Growth
40.45
N/A
52 Week Low
$14.20
$48.17
52 Week High
$28.35
$68.71

Technical Indicators

Market Signals
Indicator
ACAD
KBH
Relative Strength Index (RSI) 50.95 43.61
Support Level $21.51 $48.89
Resistance Level $22.97 $52.79
Average True Range (ATR) 0.66 1.38
MACD 0.08 0.30
Stochastic Oscillator 66.67 28.77

Price Performance

Historical Comparison
ACAD
KBH

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About KBH KB Home

KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.

Share on Social Networks: